June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Antimicrobial performance of preservative agents in antiglaucoma ophthalmic solutions
Author Affiliations & Notes
  • Taiichiro Chikama
    Ophthalmology, Hiroshima Univ Grad Sch of Biomed Sci, Minami-ku, Japan
  • Nur Putri Irmayasari
    Ophthalmology, Hiroshima Univ Grad Sch of Biomed Sci, Minami-ku, Japan
  • Latief Miftahul Akhyar
    Ophthalmology, Hiroshima Univ Grad Sch of Biomed Sci, Minami-ku, Japan
  • Yoshiaki Kiuchi
    Ophthalmology, Hiroshima Univ Grad Sch of Biomed Sci, Minami-ku, Japan
  • Footnotes
    Commercial Relationships Taiichiro Chikama, None; Nur Putri Irmayasari, None; Latief Miftahul Akhyar, None; Yoshiaki Kiuchi, Alcon (F), Pfizer (F), Santen (F), Senju (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 281. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Taiichiro Chikama, Nur Putri Irmayasari, Latief Miftahul Akhyar, Yoshiaki Kiuchi; Antimicrobial performance of preservative agents in antiglaucoma ophthalmic solutions. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):281.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: We examined the antimicrobial performance of preservatives—benzalkonium chloride (BAC) at three different concentrations and the SofZia system—present in topical ocular hypotensive agents.

Methods: Four antiglaucoma ophthalmic solutions distributed in Japan—latanoprost (0.005%) with 0.02% BAC (Xalatan), bimatoprost (0.03%) with 0.005% BAC (LUMIGAN), tafluprost (0.0015%) with 0.001% BAC (TAPROS), and travoprost (0.004%) with SofZia (TRAVATANZ)—were tested for their antimicrobial activity against Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, Propionibacterium acnes, Streptococcus pneumoniae, and Candida albicans. Each drug solution (10 mL) was inoculated with 1 × 106 colony-forming units of each organism and incubated at 20° to 25°C. Samples of each mixture collected at various times from 6 h to 28 days were serially diluted in Mueller-Hinton broth (for S. aureus, P. aeruginosa, E. coli and C. albicans), BL liquid medium (for S. pneumonia) or GAM liquid medium (for P. acnes) and plated in triplicate on tryptic soy agar (for S. aureus, P. aeruginosa, E. coli), BL agar plus horse blood (for S. pneumonia), GAM agar (for P. acnes) or Sabouraud dextrose agar (for C. albicans). Culture plates were incubated at 30° to 35°C for >3 days or at 20° to 25°C for >5 days, respectively, and the number of colonies was then counted.

Results: Latanoprost with 0.02% BAC completely inhibited bacterial growth after incubation for 24 h as well as fungal growth at 6 h. Bimatoprost with 0.005% BAC completely inhibited bacterial and fungal growth after incubation for 6 h. Tafluprost with 0.001% BAC completely inhibited bacterial growth after incubation for 7 days as well as fungal growth after incubation for 14 days. Travoprost with SofZia completely inhibited bacterial growth at 6 h but had no effect on fungal growth.

Conclusions: All four ophthalmic solutions performed well in tests of their antimicrobial activity. Only travoprost with the SofZia preservative system did not inhibit the growth of C. albicans within 28 days.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×